Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a biotechnology leader focused on developing gene therapies for rare neuromuscular and cardiac disorders, including Duchenne muscular dystrophy. This news hub provides investors and researchers with timely updates on the company's progress in advancing precision genetic medicines.
Access comprehensive coverage of SLDB's press releases, clinical trial milestones, financial disclosures, and strategic partnerships. Our curated news collection simplifies tracking critical developments in gene therapy innovation and regulatory advancements.
Key updates include announcements related to therapeutic pipelines, scientific collaborations, and market-moving events. Bookmark this page for streamlined access to verified information directly impacting SLDB's research trajectory and industry position.
Solid Biosciences Inc. announced the issuance of 38,508 restricted stock units to two new employees under the 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years subject to continued service with the company, in line with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Solid Bioscience (SLDB)?
What is the market cap of Solid Bioscience (SLDB)?
